Preclinical studies of Apogossypolone: a new nonpeptidic pan small-molecule inhibitor of Bcl-2, Bcl-XL and Mcl-1 proteins in Follicular Small Cleaved Cell Lymphoma model

TLDR

The abstract has Background, Purpose+Mechanism combined, Findings multiple. The instruction: "If a sentence is labeled with multiple labels, its information should influence both the Purpose and the Findings summaries appropriately." So the sentence that has Purpose and Mechanism should contribute to both Purpose and Mechanism summaries. Purpose sentence: "The study aimed to evaluate the efficacy of the non‑peptidic small‑molecule inhibitor Apogossypolone (ApoG2) against Bcl‑2 family proteins in follicular small‑cleaved cell lymphoma cells and patient‑derived lymphoma cells." Mechanism sentence: "The authors tested ApoG2 in the WSU‑FSCCL cell line and in lymphoma cells isolated from patients, assessing its impact on cell growth and apoptosis pathways." But we might combine: "The authors evaluated ApoG2, a potent non‑peptidic small‑molecule inhibitor of Bcl‑2 family proteins, in the WSU‑FSCCL cell line and patient‑derived lymphoma cells." That covers both purpose and mechanism? Let's craft: Background: "Elevated expression of anti‑apoptotic Bcl‑2 family proteins is associated with poor survival in follicular lymphoma." Purpose: "The study aimed to evaluate the efficacy of the non‑peptidic small‑molecule inhibitor Apogossypolone (ApoG2) against Bcl‑2 family proteins in follicular small‑cleaved cell lymphoma." Mechanism: "The authors tested ApoG2 in the WSU‑FSCCL cell line and in lymphoma cells isolated from patients, measuring its impact on cell growth and apoptosis." Findings: "ApoG2 inhibited WSU‑FSCCL growth with an IC50 of 109 nM, activated caspases‑9, ‑3, and ‑8 and induced PARP and AIF cleavage, and achieved 84 % and 63 % tumor inhibition in intravenous and intraperitoneal xenograft models, indicating its potential as an FL therapeutic." Check sentence count: 4.

Abstract

Abstract Elevated expression of anti-apoptotic Bcl-2 family proteins have been linked to a poor survival rate of patients with Follicular Lymphoma (FL). This prompted us to evaluate a very potent non-peptidic Small-Molecule Inhibitor (SMI) targeting Bcl-2 family proteins, Apogossypolone (ApoG2) using follicular small cleaved cell lymphoma cell line (WSU-FSCCL) and cell isolated from lymphoma patients. ApoG2 inhibited the growth of WSU-FSCCL significantly with a 50% growth inhibition of cells (IC 50 ) of 109 nM and decreased cell number of fresh lymphoma cells. ApoG2 activated caspases-9, -3, and -8, and the cleavage of Poly (ADP-ribose) polymerase (PARP) and Apoptosis Inducing Factor (AIF). In the WSU-FSCCL-SCID xenograft model, ApoG2 showed a significant anti-lymphoma effect, with %ILS of 84% in the intravenous and 63% in intraperitoneal treated mice. These studies suggest that ApoG2 can be an effective therapeutic agent against FL.